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Obesity is recognized as a major health problem worldwide. Genetic factors play a major role in obesity, and genomewide
association studies have provided evidence that several common variants within the fat mass- and obesity-associated (FTO)g e n e
are signiﬁcantly associated with obesity. Very limited data is available on FTO in the Italian population. Aims of our study are
to investigate: (1) the association of FTO gene SNPs rs9939609 and rs9930506 with body mass index (BMI) and obesity-related
parameters in a large cohort (n = 752) of Italian obese subjects; (2) the association between the two FTO SNPs and age of onset of
obesity. Our results demonstrate a strong association between FTO SNPs rs9939609 (P<0.043) and rs9930506 (P<0.029) with
BMI in the Italian population. FTO rs9930506 was signiﬁcantly associated with higher BMI in a G allele dose-dependent manner
(BMI + 1.4kg/m 2 per G allele). We also observed that the association with BMI of the two FTO variants varied with age, with the
carriers of the risk alleles developing an increase in body weight earlier in life. In conclusion, our study further demonstrates a role
of the genetic variability in FTO on BMI in a large Italian population.
1.Introduction
Obesity is considered a worldwide epidemic in modern so-
cieties, aﬀecting all ages, genders, and ethnic groups. In-
creased adiposity is due to the interaction between a genet-
ic background and environmental factors, particularly exces-
sive food intake and reduced physical activity. Although the
obesity epidemic has been certainly driven by lifestyle and
environmental changes, it is also clear that there is individual
variation in response to these factors, suggesting a strong
genetic predisposition. In recent years, of the many genes
studied for obesity, the FTO (fat mass- and obesity- asso-
ciated) gene has been proven consistently to be associated
with increased body mass index (BMI). Since its discovery in
2007 in genomewide association studies for type 2 diabetes
[1], several other studies have conﬁrmed the association in
diﬀerent populations [2–4]. Of the many found associated,
the FTO rs9939609 single nucleotide polymorphism (SNP),
located in the ﬁrst intron, is of particular interest since it was
the ﬁrst to be found to be associated with obesity and has
been constantly replicated through independent studies of
largeCaucasianpopulations[2,3].Itwasestimatedthateach
copy of the highly frequent (40–50% in the general popula-
tion) FTO rs9939609 minor allele (i.e., A allele) corresponds
to approximately 1.5-kg heavier body weight [1].
FTOismainlyexpressedinthehypothalamus,anditmay
play important roles in the management of energy home-
ostasis [5], nucleic acid demethylation, and in the regulation
of body fat masses by lipolysis [6].2 Experimental Diabetes Research
Other than BMI, FTO gene SNPs have been shown to
associate with a number of metabolic-related traits, such as
higher fasting insulin, glucose, triglycerides and lower HDL
cholesterol [7], waist circumference [8, 9], and body weight
[10].
So far, very limited data is available on the relationship
between FTO gene and obesity in the Italian adult popula-
tion. The only study published in a cohort from Sardinia
[10] showed association between the FTO rs9939609 SNP
and BMI, total body weight, and hip circumference. Fur-
thermore, a second FTO SNP, the rs9930506, showed in
this population an even stronger association [10]c o m p a r e d
to the rs9939609 SNP. It should be pointed out that this
population is from Sardinia, an Italian island that shows
peculiar genetic characteristics that may diﬀer from the rest
of the Italian population [11].
Various studies have investigated the eﬀect of FTO var-
iants on BMI and weight in a longitudinal perspective, and
whether it inﬂuences weight gain during adult life [12, 13].
Interestingly, a stronger correlation between BMI and FTO
single nucleotide polymorphisms is most commonly seen in
cohorts of children and young adults [14, 15].
Aims of our study are therefore: (1) to investigate the
association of the FTO gene SNPs rs9939609 and rs9930506
with BMI and obesity-related parameters in a large cohort
(n = 752) of Italian obese population; (2) to examine the
association between the two FTO SNPs and age of onset of
obesity.
2. Methods
2.1. Study Group. A total of 950 subjects were studied. 752
consecutive unrelated obese (BMI ≥ 30kg/m2) Caucasians
were recruited from the Day-Hospital of the Department
of Clinical Sciences, University of Rome “Sapienza”. They
underwent complete medical evaluation and a standard 75g
oral glucose tolerance test (OGTT) with measurements of
glucose and insulin at baseline and after 30, 60, 90, and 120
minutes. All individuals provided informed consent prior to
inclusion in the study. The study was approved by the local
research ethics committee.
Nonobesesubjects(n=198)wererecruitedfromsubjects
participating in a community-based health screening. All
subjects were unrelated, and the only inclusion criteria in the
control group for obesity was a BMI <27kg/m2.I nnonobese
subjects a complete medical history was obtained together
with laboratory parameters including total cholesterol, HDL,
LDL, triglycerides, blood glucose, and fasting plasma insulin.
In all subjects diagnosis of type 2 diabetes was based on
either fasting plasma glucose ≥ 7.0mmol/L (126mg/dL), or
plasma glucose ≥ 11.1mmol/L (200mg/dL) 2 hours after a
75gglucoseloadduringtheOGTT.Alsoapreviousdiagnosis
ofdiabetesand/orahistoryofhypoglycaemictreatmentwere
considered.
2.2.Biochemistry. Glucose,insulin,cholesterol,HDL-choles-
terol, and triglycerides (TGs) were measured as previously
described [16], after an overnight fast. Glucose levels below
100mg/dL, HDL > 40mg/dL for men and > 50mg/dL for
women, and triglycerides < 150mg/dL were taken as normal
limits.
Serum alanine (ALT) and aspartate aminotransferase
(AST) levels in fasting subjects were assayed using a Hita-
chi 737 analyzer (Boehringer-Mannheim Diagnostics, Indi-
anapolis, IN). Homeostasis model assessment of insulin re-
sistance (HOMA-IR) and insulin sensitivity index (ISI) in-
dices were calculated as previously shown by Matthews et al.
[17]a n dM a t s u d aa n dD e f r o n z o[ 18].
2.3. Genotyping Assay. Genomic DNA samples were extract-
ed from peripheral blood, using a modiﬁed salting out pro-
cedure from Miller et al. [19].
In this study, we have used locked nucleic acid (LNA)
hybridizationprobes(ﬂuorometricmethod)asallele-speciﬁc
tools in genotyping assays in order to analyze each SNPs
(rs9930506 and rs9939609). Real time PCR was performed
usingiQ5MulticolorReal-Time(Bio-RadLaboratories),and
data analysis was conducted with the corresponding software
interface. In a 25μL reaction volume 300nM of each PCR
p r i m e r ,2 8 0n Mo fe a c hL N Ap r o b e ,1 Xi QS u p e r m i x( B i o -
Rad Laboratories), and 10ng of genomic DNA were added.
PCR primers and LNA probes were designed and synthe-
sized by Sigma-Aldrich Life Science (further data on primers
and probes are available upon request).
Some genomic DNA samples used for real-time PCR op-
timization were sequenced to validate the observed allelic
discrimination curves and genotypes.
2.4. Statistical Analysis. Categorical variable distributions
were compared by the Pearson χ2.D i ﬀerences between con-
tinuous variables across the genotype classes were evaluated
by ANOVA including gender, age, and BMI as covariates.
Skewed variables were logarithmically transformed prior to
entering the analyses. Linkage disequilibrium between the
rs9939609 and rs9930506 SNPs was assessed by calculating
the disequilibrium statistics Δ [20]a n dD   [21]. The sign
of D  (positive or negative) depends on the arbitrary choice
of the alleles paired at the two loci and indicates whether
the same or opposite allelic association is present. The dif-
ferences in the variables within the same group before and
after bariatric surgery were compared with paired-samples
statistics. All statistical analyses were performed with SPSS
17.0 statistical package.
3. Results
3.1. Characteristics of the Study Population. Clinical charac-
teristics of the study subjects stratiﬁed by classes of BMI
(group A, nonobese: BMI < 27kg/m2;g r o u pB ,c l a s sI / I I
obese: BMI = 30–39.9kg/m2; group C, class III obese: BMI ≥
40kg/m2) are reported in Table 1. Overall, 752 (79%) of the
950 study subjects were obese (422 with class III obesity),
whereas 209 (22%) subjects had T2D.
Generally, as expected, many clinical and biochemical
data worsened signiﬁcantly with increasing BMI, with class
III obese subjects showing the highest levels of fasting bloodExperimental Diabetes Research 3
Table 1: Clinical characteristics of study subjects stratiﬁed for BMI.
N Group A
Nonobese 198
Group B
Class I/II obese 330
P
Av e r s u sB
Group C
Class III obese 422
P
Av e r s u sC
P
Bv e r s u sC
Women/men 159/39 222/108 <0.001 303/119 <0.01 NS
Age (yr) 49 (45–55) 48 (34–58) NS 43 (35–51) <0.001 0.005
Body mass index
(kg/m2)a 23.0 (21.3–24.7) 35.7 (32.9–38.1) <0.001 46.2 (42.8–51.1) <0.001 <0.001
WAIST (cm) 95.5 (91–100) 112 (105–120) 0.045 132.5 (123–142) <0.001 <0.001
SBP (mm/Hg) 120 (115–135) 130 (120–140) NS 130 (120–140) NS NS
DBP (mm/Hg) 80 (70–86) 80 (75–90) NS 85 (80–90) <0.001 <0.001
Triglycerides (mg/dL) 85.5 (65.6–120.3) 127.3 (85.9–181) <0.001 125 (88.6–163) <0.001 NS
Total cholesterol
(mg/dL) 209 (187.2–234) 203 (178–234) NS 195 (170–218.3) <0.001 <0.003
HDL cholesterol
(mg/dL) 59 (50–67) 47.3 (40.3–56.6) <0.001 45.8 (39.8–53) <0.001 <0.033
LDL cholesterol
(mg/dL) 126 (108–147) 124.2 (105–149) NS 115 (95.1–139.6) <0.003 <0.021
ALT (U/L) 23 (13.1–34.5) 27.5 (19.2–40) NS 29.1 (20.7–45.6) NS NS
AST (U/L) 20 (18–25) 20 (16–27) NS 20 (16–28) NS NS
Fasting blood glucose
(mg/dL) 92 (84–100) 93 (82–118) NS 95 (85–111) <0.001 NS
Fasting blood insulin
(μU/mL) 9.9 (7–15.2) 18.8 (13–30) <0.001 29 (19.5–47.3) <0.001 <0.001
HOMA-IR (U) 2 (1.5–3.3) 3.9 (2.6–6.7) <0.001 6.2 (4.1–10.7) <0.001 <0.001
ISI (U) 4.6 (2.9–7.8) 2.8 (1.8–4.4) <0.001 1.9 (1.2–2.8) <0.001 <0.001
Type 2 diabetes n (%) 5 (2.5) 101 (30.6) <0.001 103 (24.4) <0.001 <0.046
aBMI was calculated as body weight (kg)/height (m2). Values are medians and interquartile ranges. Abbreviations: SBP, systolic blood pressure; DBP, diastolic
bloodpressure;HDL,highdensitylipoprotein;LDL,lowdensitylipoprotein;ALT,alaninetransaminase;AST,aspartatetransaminase;HOMA-IR,homeostatic
model assessment of insulin resistance; ISI, insulin sensitivity index. Non-obese: BMI < 27 kg/m2; class I/II obese: BMI = 30-39.9 kg/m2; class III obese: BMI
≥ 40 kg/m2.
glucose and insulin, lipids, transaminases, HOMA-IR, and
lower values of ISI. In the control normal-weight group all
parameters were within normal range, with only 5 subjects
with diabetes.
3.2. FTO Allele Frequencies and Linkage Disequilibrium. In
the whole population risk-allele frequencies of the rs9939609
(A) and rs9930506 (G) FTO gene were 0.48 and 0.50,
respectively, similar to HapMap (haplotype map of the hu-
man genome) population frequencies for rs9939609 (A) alle-
le in CEPH Europeans and for rs9930506 (G) allele in CEU
Europeans.
The two SNPs showed a strong linkage disequilibrium
(Δ = 0.88, D
 = 0.90, P<0.0001). Nevertheless, because of a
diﬀerent eﬀect observed in Italian subjects [10], we analyzed
the two variants separately and as haplotypes in our study
cohort.
3.3. Association Study of the rs9939609 and rs9930506 Poly-
morphismswithBMIandT2D. Table 2 showstheassociation
of the 2 FTO variants with obesity; the rs9939609 A-allele
frequency and rs9930506 G-allele frequency in the obese
subjects were signiﬁcantly higher than in the lean group
(P<0.027 and P<0.013, resp.). When the association
was adjusted by age and sex, signiﬁcance was maintained,
although at lower P v a l u e s ,s u g g e s t i n gas t r o n ge ﬀect of these
parameters (P<0.038 and P<0.015, resp.).
When we stratiﬁed for BMI levels, no signiﬁcant diﬀer-
ence in rs9939609 A-allele frequency was observed between
class I/II obesity and class III obesity (Table 2(a)). Similar
results were observed for rs9930506 G-allele frequency bet-
ween class I/II obesity and class III obesity (0.51 and 0.52,
resp.)(Table 2(b)).Withreferencetothers9939609(A)allele
we should point out that we did not observe a signiﬁcant
diﬀerence between controls and class I/II obesity. This may
be explained by the fact that this SNP has a weaker eﬀect
in Italian population, as also demonstrated by the study of
Scuteri et al. [10]. Conversely, rs9930506 was, in the same
population, signiﬁcantly associated with class I/II obesity.
We next tested the association with T2D. A-allele fre-
quencies for rs9939609 polymorphism were not signiﬁcantly
diﬀerent between T2D and nondiabetic individuals (0.51
and 0.50, resp. P = NS); similarly, no signiﬁcant diﬀerences
between T2D and nondiabetic subjects were observed for the
rs9930506 G-allele (0.51 and 0.52, resp. P = NS).
We then compared other clinical parameters according
to genotype classes for both SNPs. There were no signiﬁcant
diﬀerences between the three genotypes in fasting blood
glucose and insulin levels, plasma concentration of ALT4 Experimental Diabetes Research
Table 2: (a) Association study of FTO rs9939609 polymorphism with obesity. (b) Association study of FTO rs9930506 polymorphism with
obesity.
(a)
Genotype n (%)
A-allele frequency (%) P Padj
n TT TA AA
Stratiﬁed on BMI
Nonobese 198 68 (34.3) 90 (45.5) 40 (20.2) 43.0 <0.027 <0.038
Obese 752 195 (25.9) 357 (47.5) 200 (26.6) 50.3
Stratiﬁed on BMI
Nonobese 198 68 (34.3) 90 (45.5) 40 (20.2) 43.0
Class I/II obese 330 88 (26.7) 152 (46.1) 90 (27.2) 50.3 <0.066∗ <0.075∗
Class III obese 422 107 (25.4) 205 (48.6) 110 (26.0) 50.4 <0.038∗ <0.057∗
(b)
Genotype n (%) G-allele frequency
(%)
P Padj
n AA AG GG
Stratiﬁed on BMI
Nonobese 198 67 (33.8) 90 (45.5) 41 (20.7) 43.4
Obese 752 190 (25.3) 346 (46.0) 216 (28.7) 51.7 <0.013 <0.015
Stratiﬁed on BMI
Nonobese 198 67 (33.8) 90 (45.5) 41 (20.7) 43.4
Class I/II obese 330 86 (26.1) 149 (45.2) 95 (28.7) 51.4 <0.043∗ <0.038∗
Class III obese 422 104 (24.6) 197 (46.7) 121 (28.7) 52.0 <0.018∗ <0.019∗
Data are n (%). Padj values were calculated using logistic regression analysis adjusted for age and sex. Nonobese: BMI < 27kg/m2; class I/II obese:
BMI = 30–39.9kg/m2; class III obese: BMI ≥ 40kg/m2. ∗versus nonobese
and AST levels, total cholesterol, HDL- and low density
lipoprotein- (LDL-)cholesterol, and circulating triglycerides.
We also tested for an association with surrogate indices of
insulin resistance (homeostatic model assessment of insulin
resistance and Matsuda insulin sensitivity index), but no
diﬀerences were found for both SNPs (data not shown). The
only associations were observed between the FTO gene SNPs
and BMI, sex, and age (Table 3). Interestingly, in our Italian
population the rs9930506 showed the strongest association
with BMI (P<0.029) and waist circumference (P<0.006).
Speciﬁcally, homozygotes for the G-allele of this SNP were
2.8BMI units heavier than homozygotes for the A-allele
(Table 3). Moreover, the rs9930506 G allele was signiﬁcantly
associated with higher BMI, in a G allele dose-dependent
manner (BMI + 1.4kg/m2 per G allele). A similar trend
was observed for homozygotes for the A-allele of rs9939609
polymorphism although with a weaker signiﬁcance (P<
0.043).
Homozygotes for the G-allele of the rs9930506 SNP were
also signiﬁcantly younger than homozygotes for the A-allele
(P<0.013) (Table 3), and a similar trend was observed for
homozygotes for the A-allele of rs9939609 polymorphism
(P<0.006) (Table 3).
3.4. Association Study of the rs9939609 and rs9930506 Poly-
morphisms with Age. We further evaluated the distribution
of the rs9939609 and rs9930506 FTO SNPs genotypes ac-
cording to age, stratifying the study population in younger
subjects (<46 years of age, median of the whole population)
and older subjects (≥46 years of age). The rs9930506 G-
allele frequency in younger subjects was signiﬁcantly higher
than in older group (0.54 versus 0.46, P<0.004) and
similarly for rs9939609 A-allele frequency (0.53 versus 0.45,
P<0.002). Further stratiﬁcation in quartiles of age showed
that subjects in the 75th quartile (>55 years) had a much
lower frequency of “at risk” FTO alleles (rs9939609 (A) =
0.42 and rs9930506 (G) = 0.44) compared to subjects in the
25th quartile (age > 35 years, 0.53 A allele and 0.54 G allele),
ad i ﬀerence that was highly signiﬁcant (P<0.01). Since
class III obese were younger they might explain most of the
diﬀerenceoffrequencydistributionofthers9930506G-allele
and of the rs9939609 A-allele between younger and older
subjects. In order to analyze this point we have performed
two separate analyses in our population: (1) we repeated the
sameanalysesinTable 3 excludingtheclassIIIobesesubjects,
and association with age was still highly signiﬁcant (data not
shown, P<0.01); (2) we also repeated the same analyses inExperimental Diabetes Research 5
Table 3: Association of rs9930506 and rs9939609 SNPs with age, BMI, and waist.
SNP Genotype
Class (n.)
Age
(years)
BMI
(kg/m2) Waist (cm)
rs9930506
AA (257) 47 ±14 37.2 ±11.4 117.8 ±18.7
GA (436) 45 ±13 38.6 ±10.4 124.2 ±18.5
GG (257) 44 ±13 40 ±9.6 126.7 ±15.2
P <0.013∗ <0.029∗∗ <0.006∗
rs9939609
TT (263) 47 ±14 37.3 ±11.4 118.4 ±19.5
TA (448) 45 ±13 38.6 ±10.4 125 ±18.2
AA (239) 43 ±13 39.4 ±9.8 125 ±14.5
P <0.006∗ <0.043∗∗ <0.025∗
Allvaluesaremeans ±standarddeviations.BMI:bodymassindex,n.:numberofsubjects. ∗P valueswerecalculatedusingalinearregressionmodelincluding
gender, age, and BMI as covariates. ∗∗A n a l y s i sa d j u s t e df o rg e n d e ra n da g e .
Table 4: Association of rs9930506 and rs9939609 SNPs with age,
BMI,andwaistinage-matchedsubjectsselectedfromthethreeBMI
classes.
SNP Genotype
Class (n.)
Age
(years)
BMI
(kg/m2) Waist (cm)
rs9930506
AA (224) 50 ±11 36.1 ±11.2 116.1 ±18.8
GA (364) 48 ±10 37.6 ±10.6 124.8 ±18.6
GG (215) 46 ±12 38.3 ±9.5 125.5 ±15.1
P <0.010∗ <0.022∗∗ <0.005∗
rs9939609
TT (224) 50 ±11 36.1 ±11.3 116.8 ±20
TA (364) 48 ±11 37.5 ±10.5 125.1 ±18.2
AA (215) 46 ±12 38.2 ±9.6 124 ±14.6
P <0.011∗ <0.038∗∗ <0.012∗
All values are means ± standard deviations. BMI: body mass index; n.:
numberofsubjects. ∗P valueswerecalculatedusingalinearregressionmod-
el including gender, age, and BMI as covariates. ∗∗Analysis adjusted for
gender and age.
thethree subgroups,selecting age-matchedsubjectsfromthe
three BMI classes (Group A mean age 49 ± 10 years, Group
Bm e a na g e4 8± 14 years, Group C mean age 49 ± 10 years,
P = NS).
As shown in Table 4 the association between FTO SNPs
and age remained highly signiﬁcant (P<0.01).
3.5. Haplotypes Analyses from rs9939609 and rs9930506 Pol-
ymorphisms. Analysesinthehaplotypesgroupsderivedfrom
rs9939609 and rs9930506 FTO genetic polymorphisms con-
ﬁrmed the lack of association of the FTO variants with
fastingbloodglucoseandinsulinlevels,plasmaALTandAST
levels, total cholesterol, HDL- and low density lipoprotein-
(LDL-) cholesterol, triglycerides, HOMA-IR, and ISI indices
(data not shown). However the AG haplotype (homozygous
carriersof“atrisk”alleles)wasassociatedwithincreasedBMI
(P<0.026) and waist circumference (P<0.003) which
is consistent with the ﬁndings observed for the two SNPs
separately (data not shown). Furthermore, AG haplotype
carriers were signiﬁcantly younger than homozygotes for the
TA haplotype (P<0.014) (data not shown) conﬁrming the
results of the two SNPs analyzed individually.
3.6. Multivariate Analyses of FTO Polymorphisms. Due to
the strong linkage disequilibrium between rs9939609 and
rs9930506 FTO genetic polymorphisms, only rs9930506 (the
most signiﬁcant) SNP was considered for further analyses.
Since univariate analyses showed a strong association of the
rs9930506 FTO only with BMI, age, and waist, we entered
in a multiple regression model these three variables. Multiple
regressionanalysiswithBMIasadependentvariablerevealed
that the rs9930506 FTO genetic polymorphisms are associ-
ated with body mass index (P<0.029), independently of sex
(P<0.036) and age (P<0.001).
4. Discussion
4.1. Association of FTO rs9939609 and rs9930506 Polymor-
phisms with BMI. Our results demonstrate in the Italian
population a strong association between rs9939609 and
rs9930506 SNPs of the FTO gene and BMI and waist circum-
ference, in concordance with previously published studies
in other European populations [1–3, 10]. Of the 2 SNPs,
rs9930506 was the most strongly associated with BMI in our
Italianpopulation, conﬁrmingtheonlypreviousobservation
[10].Furthermore,theGalleleofrs9930506wassigniﬁcantly
associated with higher BMI in a G allele dose-dependent
manner (BMI + 1.4kg/m2 per G allele).
4.2. Association of FTO rs9939609 and rs9930506 Polymor-
phisms with Age. We also observed that the associations of
FTO rs9939609 and rs9930506 variants on body size varied
with age. Particularly, the at-risk allele frequencies for both
SNPs were signiﬁcantly higher in younger than in older
subjects, suggesting that carriers of the risk allele develop an
increase in body weight earlier in life.
There have been only a few other studies exploring the
association between FTO gene and BMI during the life
course [12, 13]. In the study by Hardy and coworkers a
longitudinal pattern of association between rs9939609 FTO
genetic variant and BMI across childhood, adolescence, and
adulthood was observed [13]. In particular, the associations
with this FTO variant strengthened during childhood and
adolescence, peaked in early adulthood, and then weakened
in adult age (after 43 years). It can be hypothesized that the6 Experimental Diabetes Research
eﬀect of FTO on body composition may be less severe in
adultlifewhenweightgainmaybemorestronglydetermined
or modiﬁed by psychosocial or environmental inﬂuences
[22] compared to younger ages.
4.3. Lack of Association of FTO Polymorphisms with Metabolic
Parameters and T2D. At variance with previous studies [7–
9], in our population FTO gene polymorphisms were asso-
ciated only with an increased BMI, but not with metabolic
parameters such as lipids, impaired glucose tolerance, or
insulin resistance. One possible explanation for these dis-
crepancies may be ascribed to the relatively young age of
our population (median 46 years), with >50% of carriers
of the FTO risk allele that are under the median age and
with a signiﬁcant proportion of carriers that are below the
25th percentile of age (<35 years) of our cohort. Thus, these
subjects may have not yet developed age-related metabolic
abnormalities.
We also tested a possible association with T2D, but no
signiﬁcantdiﬀerencesbetweenT2Dandnondiabeticsubjects
were observed for the FTO SNPs. It has been previously
observed that the association of the SNPs (located in the
ﬁrst intron) of the FTO gene with T2D was abolished after
adjustment for BMI, indicating that the impact of FTO on
T2D was primarily due to its association with BMI [1]. Our
study population presented a prevalence of obesity of ∼79%,
and this might explain the absence of association of FTO
SNPs with T2D.
It is unclear how FTO increases the susceptibility to
develop overweight and obesity. There are no obvious evi-
dences suggesting that rs9939609 or rs9930506 are the caus-
al variants, and, indeed, there are many other variants else-
where in the gene or control elements of other genes that
are in complete linkage disequilibrium with the FTO locus.
However, based on the rapid fall-oﬀ of linkage disequilib-
rium with other SNPs beyond 47kb, it has been concluded
that the functional variant is likely to lie within this area of
the FTO gene [1].
Through the use of bioinformatics and recombinant
functional studies it has been recently demonstrated that
the FTO gene encodes a nucleic acid demethylase [23]. De-
methylation of DNA is essential for repairing exocyclic DNA
lesions, which, if left unchecked, can lead to permanent,
and sometimes deleterious, sequence changes. It is also
conceivable that the nucleic acid demethylation activity of
FTOonDNAmightregulatetheexpressionofgenesinvolved
in metabolism and that dysregulation of this process might
lead to obesity at an epigenetic level [24].
5. Conclusion
FTO is the ﬁrst and the most robust obesity susceptibility
gene of the GWAS era. Although its eﬀect size is modest,
one should not underestimate the relevance of FTO at
the population level. The observed association is common
and consistent across multiple ethnic groups and could be
inﬂuencing BMI of up to half the world’s population.
Our data conﬁrm all these ﬁndings. In particular, we
observe that the association between FTO gene and BMI
strongly inﬂuences the age of onset of obesity, with the
carriers of the “at risk” alleles showing a signiﬁcantly higher
prevalence in younger age. In conclusion, our study shows a
role of the genetic variability in FTO in the modulation of
BMI in a large Italian population.
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